Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mayo clinic tests best duration of daratumumab to keep amyloidosis at bay

NCT ID NCT05898646

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial at Mayo Clinic is testing whether longer maintenance therapy with daratumumab can improve survival for people with AL amyloidosis. About 96 adults who have already responded to initial daratumumab treatment will be randomly assigned to shorter or longer maintenance. The goal is to see which approach better prevents the disease from coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Daratumumab (a monoclonal antibody)
What this could lead to
If successful, this trial could show that longer maintenance therapy with daratumumab helps keep AL amyloidosis from returning and improves survival.
What could go wrong
This is a phase II trial with only 96 participants, so results are preliminary. Daratumumab may cause side effects, and it is not yet known if longer maintenance is truly better than shorter.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis Immunoglobulin Light-chain Amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AL AMYLOIDOSIS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Mayo Clinic in Arizona

    RECRUITING

    Scottsdale, Arizona, 85259, United States

    Contact Email: •••••@•••••

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.